Publications by authors named "Gilliosa Spurrier"
Article Synopsis
- The article provides updated guidelines for clinicians on systemic therapy options for melanoma, based on a systematic review by the American Society of Clinical Oncology Expert Panel.
- New recommendations include using neoadjuvant pembrolizumab for resectable stage IIIB to IV melanoma, and adjuvant nivolumab or pembrolizumab for stage IIB-C disease.
- Additionally, certain older treatments are no longer recommended for specific melanoma types, and new options are suggested for unresectable or metastatic cases.
Article Synopsis
- The text outlines guidance for clinicians on the use of systemic therapy for melanoma based on a systematic review and meta-analysis.
- It includes recommendations for treating different melanoma stages, specifying therapies for both wild-type and mutant cutaneous melanoma.
- Additionally, it mentions the lack of specific recommendations for neoadjuvant therapy and uveal melanoma, while suggesting that mucosal melanoma patients may receive similar treatments as those with cutaneous melanoma.
Purpose: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in overall survival amongst innovative products may be difficult to measure in clinical trials, and their use may be associated with increased toxicity profiles. Therefore, HTA agencies increasingly require information on HRQoL for the assessment of such drugs.
View Article and Find Full Text PDF